Hepatitis B
Hepatitis B is an infectious disease caused by Hepatitis B Virus (HBV), primarily leading to inflammatory lesions in liver and can cause multiple organ damage. It is the most common cause of death related to liver cirrhosis, liver cancer, and viral hepatitis. Hepatitis B is a continuous global public health challenge that brings enormous pain and heavy burden to society and patient families. Current antiviral drugs, while effective at suppressing the virus, cannot fully cure HBV infection. Upon discontinuation of treatment, the immune system's tolerance of HBV-specific T cells often results in viral rebound and disease recurrence.
Lentiviral Vector for Hepatitis B Immunotherapy
Therapeutic vaccines can selectively increase the level of HBV specific T cells. Among them, lentiviral vector vaccines have received great attention in the field of hepatitis B immunotherapy due to their notable advantages.
Enhanced immunogenicity - Lentiviral vectors effectively deliver HBV antigens to Antigen-Presenting Cells (APCs), boosting immunogenicity and triggering a robust and persistent immune response, thus achieving protective immunity against hepatitis B.
Targeted antigen delivery - The lentiviral vectors can accurately target and deliver HBV antigen to the primary site of infection. This targeted delivery ensures that immune responses are generated where they are most needed, thereby optimizing the effectiveness of the vaccine.
Improved antigen presentation - Lentiviral vectors can be engineered to enhance APC's ability to process and present antigens, facilitating more effective activation of T cells and antibody production.
Inducing persistent immunity - A key feature of lentiviral vectors is their ability to provide sustained transgene expression, which ensures the induction of long-term immunity. The prolonged immune response persists is crucial for preventing chronic HBV infection and ensuring lasting protection.
Safety profile - The safety of lentiviral vectors has been thoroughly validated across various applications, including gene therapy and vaccine development. Their favorable profile, combined with strong clinical translatability, positions them as promising candidates for HBV vaccine development.
Lentiviral Vector Based Therapeutic HBV Vaccines Developed by Jinwei
Advanced therapeutic vaccines have been developed on various biological platforms, including recombinant proteins, DNA plasmids, peptides, and immune complexes. While clinical trial outcomes for these platforms have been variable, they have provided valuable insights for future developments. Jinwei has developed a non-integrated lentiviral vector therapeutic HBV vaccine that effectively transduces and activates non-dividing professional antigen-presenting cells, such as dendritic cells and macrophages. Various experimental results also indicate that the vaccine exhibits bright prospects for application in hepatitis B immunotherapy.
The lentiviral vector therapeutic HBV vaccine enhances immunogenicity, ensures targeted antigen delivery and provides long-lasting immunity, making it a promising tool in the fight against chronic HBV infection. Jinwei is well-positioned to address several key challenges in vaccine development through its lentiviral vector-based therapeutic vaccines, revolutionizing hepatitis B immunotherapy and significantly improving both the prevention and treatment of the disease.
Contact Us
